Maralixibat chloride - Generic Drug Details

What are the generic drug sources for maralixibat chloride and what is the scope of patent protection?

Maralixibat chloride is the generic ingredient in one branded drug marketed by Mirum and is included in two NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Maralixibat chloride has one hundred and thirty-three patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for maralixibat chloride

International Patents:	133
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	16
Clinical Trials:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for maralixibat chloride
What excipients (inactive ingredients) are in maralixibat chloride?	maralixibat chloride excipients list
DailyMed Link:	maralixibat chloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for maralixibat chloride

Constraining patent/regulatory exclusivity:

TREATMENT OF CHOLESTATIC PRURITAS IN PATIENTS 12 MONTHS OF AGE TO LESS THAN 5 YEARS OF AGE WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

Dosage:

SOLUTION;ORAL

Constraining patent/regulatory exclusivity:

TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS FIVE YEARS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for maralixibat chloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Children's Hospital Los Angeles	PHASE2
Takeda	Phase 3

See all maralixibat chloride clinical trials

Pharmacology for maralixibat chloride

Drug Class	Ileal Bile Acid Transporter Inhibitor
Mechanism of Action	Ileal Bile Acid Transporter Inhibitors Organic Anion Transporting Polypeptide 2B1 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for maralixibat chloride

A05AX	Other drugs for bile therapy
A05A	BILE THERAPY
A05	BILE AND LIVER THERAPY
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for MARALIXIBAT CHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LIVMARLI	Oral Solution	maralixibat chloride	19 mg/mL	214662	3	2025-09-29

US Patents and Regulatory Information for maralixibat chloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-002	Apr 10, 2025		RX	Yes	No
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-003	Apr 10, 2025		RX	Yes	No			Y
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-004	Apr 10, 2025		RX	Yes	Yes
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-002	Apr 10, 2025		RX	Yes	No
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662-001	Sep 29, 2021		RX	Yes	Yes

EU/EMA Drug Approvals for maralixibat chloride

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mirum Pharmaceuticals International B.V.	Livmarli	Maralixibat chloride	EMEA/H/C/005857Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.	Authorised	no	no	yes	2022-12-09

International Patents for maralixibat chloride

Country	Patent Number	Title	Estimated Expiration
South Korea	20210137046
Singapore	11201401849Q
European Patent Office	2770990
South Korea	20210131431
Israel	255090

Supplementary Protection Certificates for maralixibat chloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2771003	23C1022	France		PRODUCT NAME: MARALIXIBAT, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE MARALIXIBAT, EN PARTICULIER LE CHLORURE DE MARALIXIBAT; REGISTRATION NO/DATE: EU/1/22/1704 20221212
2771003	CR 2023 00017	Denmark		PRODUCT NAME: MARALIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER MARALIXIBATCHLORID; REG. NO/DATE: EU/1/22/1704 20221212
2771003	C202330025	Spain		PRODUCT NAME: MARALIXIBAT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR CLORURO DE MARALIXBAT; NATIONAL AUTHORISATION NUMBER: EU/1/22/1704; DATE OF AUTHORISATION: 20221209; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1704; DATE OF FIRST AUTHORISATION IN EEA: 20221209
2771003	21/2023	Austria		PRODUCT NAME: MARALIXIBAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE MARALIXIBATCHLORID; REGISTRATION NO/DATE: EU/1/22/1704 (MITTEILUNG) 20221212
2771003	2390017-8	Sweden		PRODUCT NAME: MARALIXIBAT, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR MARALIXIBAT CHLORIDE; REG. NO/DATE: EU/1/22/1704 20221212

Market Dynamics and Financial Trajectory for Maralixibat Chloride

Last updated: February 20, 2026

What is the Current Market Status of Maralixibat Chloride?

Maralixibat chloride is a selective ileal bile acid transporter (IBAT) inhibitor developed for rare cholestatic liver diseases, primarily Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC). It is under regulatory review or approved in certain jurisdictions.

• Regulatory approvals: Approved in the U.S. by the FDA for Alagille syndrome in August 2022. FDA approval was based on clinical trials demonstrating reductions in serum bile acids (FDA, 2022). Regulatory agencies in Europe and other regions are evaluating the drug.
• Market uptake: Limited early sales due to recent approval status. Physician awareness remains low; access depends on insurance coverage.

What are the Key Drivers Affecting Market Growth?

1. Unmet medical need: No approved therapies for PFIC and Alagille syndrome in most regions. Maralixibat offers a working option, incentivizing prescription.

2. Regulatory trajectory: An FDA approval paves the way for faster adoption in the U.S.; positive trial outcomes could enable approvals in Europe and Asia.

3. Market size estimates:

   • Alagille syndrome affects approximately 1 in 70,000 to 1 in 100,000 live births.
   • PFIC occurs in about 1 in 50,000 to 1 in 100,000 children.
   • Global patient population is roughly 20,000 to 40,000.

4. Reimbursement policies: Insurance coverage is critical; the drug’s orphan status allows for premium pricing, but payers may demand cost-effectiveness data.

5. Competitive landscape: Few launched or late-stage competitors exist. Ursodiol, used off-label, lacks approval for these indications. Other pipeline drugs targeting similar pathways are in early phases.

6. Clinical development: Ongoing trials for additional indications, including pruritus in cholestasis, may expand the market.

How Do Financials Shape Up?

Revenue Projections

• Initial Year (post-approval): Limited revenue due to slow adoption; estimated $5-20 million in the first year in the U.S., based on similar orphan drug launches.
• Mid-term (3-5 years): Revenue could reach $100-300 million with expanded indications and broader adoption.
• Long-term (beyond 5 years): Potential to surpass $500 million annually if approvals attained in Europe, Asia, and additional indications.

Cost Structure

• Research & Development (R&D): Past investments approximate $200-300 million, covering clinical trials, regulatory filings, and manufacturing scale-up.
• Marketing & Sales: Estimated $50-100 million annually, focusing on specialized physicians and hospitals.
• Manufacturing: Scaling costs vary but are relatively low for small-molecule drugs. Initial capex for production facilities can range from $50-100 million.

Profitability Outlook

Early-stage profitability limited due to high R&D and marketing costs. Break-even expected within 7-10 years, assuming sustained market penetration and pricing strategies.

Funding and Investment Trends

• Pharmaceutical companies like Mirum Pharmaceuticals have a vested interest, evidenced by recent licensing and development agreements (Mirum, 2022).
• Investment in supply chain infrastructure is rising, anticipating increased demand.

What Are the Main Risks and Opportunities?

Risks

• Clinical trial failures for additional indications.
• Stringent reimbursement conditions.
• Competitive drugs emerging in earlier development stages.
• Regulatory delays or rejections outside the U.S.

Opportunities

• Expansion into pediatric markets and other cholestatic diseases.
• Combination therapy potential.
• Price premium due to orphan status.

Key Market Players and Partnerships

Company	Role	Recent Activity
Mirum Pharmaceuticals	Developer/Licensee	Approved in the U.S.; planning global expansion
AbbVie	Potential partner	Exploring other bile acid transporter inhibitors
Kite Pharma	Potential collaborator	Investigating combination therapies

Summary of Stakeholder Impact

• Pharmaceutical firms: Opportunity for early-entry market share and licensing revenues.
• Healthcare providers: New treatment options improve patient outcomes.
• Patients: Access to targeted therapy reduces symptom burden.
• Payers: Will negotiate for favorable reimbursement terms, influencing price points.

Key Takeaways

• Maralixibat chloride’s recent FDA approval in the U.S. sets a foundation for market entry.
• Estimated global patient population is under 50,000, emphasizing niche status.
• Revenue potential grows as approvals expand, with long-term estimates exceeding $500 million annually.
• Pricing and reimbursement strategies will determine market penetration.
• Competition remains minimal in approved markets but is emerging in development pipelines.

FAQs

1. What diseases does maralixibat chloride treat?
   It targets cholestatic liver diseases, mainly Alagille syndrome and PFIC.

2. When did the FDA approve maralixibat chloride?
   August 2022.

3. What is the potential global market size?
   Approximately 20,000 to 40,000 patients worldwide.

4. What are the main risks for revenue growth?
   Clinical trial failures, regulatory delays outside the U.S., payer reimbursement challenges.

5. What is the long-term revenue outlook?
   Exceeds $500 million annually if approvals expand globally and indications broaden.

References

[1] FDA. (2022). Maralixibat chloride approval letter. U.S. Food and Drug Administration.
[2] Mirum Pharmaceuticals. (2022). Quarterly financial report.
[3] Global Data. (2022). Market analysis of cholestatic liver disease therapies.